rhenium-186 hedp has been researched along with Disease Exacerbation in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bloemendal, HJ; Bouman-Wammes, EW; de Klerk, JMH; van den Eertwegh, AJM; van Dodewaard-de Jong, JM; Verheul, HMW | 1 |
| Albers, P; Biersack, HJ; Ezziddin, S; Fimmers, R; Guhlke, S; Joe, A; Knapp, FF; Manka-Waluch, A; Palmedo, H; Reinhardt, M; Roedel, R; Schmidt-Wolf, IG | 1 |
| Al-Deen, A; Buffa, FM; Chittenden, S; Cook, G; Dearnaley, DP; Flux, G; Gadd, J; Guy, M; Horwich, A; Huddart, RA; McCready, VR; Norman, AR; O'Sullivan, JM; Pomeroy, K; Treleaven, J | 1 |
3 trial(s) available for rhenium-186 hedp and Disease Exacerbation
| Article | Year |
|---|---|
A Phase 1 Trial of Cabazitaxel Combined With 188Re-Hydroxyethylidene Diphosphonate in Patients With Metastatic Castration-Resistant Prostate Cancer Who Progressed on or After a Docetaxel-Containing Treatment: The ReCab Trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease Progression; Docetaxel; Etidronic Acid; Humans; Male; Middle Aged; Neoplasm Metastasis; Organometallic Compounds; Prostatic Neoplasms, Castration-Resistant; Taxoids; Treatment Outcome | 2017 |
Repeated bone-targeted therapy for hormone-refractory prostate carcinoma: tandomized phase II trial with the new, high-energy radiopharmaceutical rhenium-188 hydroxyethylidenediphosphonate.
Topics: Aged; Bone Neoplasms; Disease Progression; Dose-Response Relationship, Radiation; Etidronic Acid; Humans; Male; Organometallic Compounds; Pain Measurement; Pain, Intractable; Palliative Care; Prospective Studies; Prostatic Neoplasms; Radiotherapy Dosage; Rhenium; Treatment Outcome | 2003 |
High activity Rhenium-186 HEDP with autologous peripheral blood stem cell rescue: a phase I study in progressive hormone refractory prostate cancer metastatic to bone.
Topics: Bone and Bones; Bone Neoplasms; Combined Modality Therapy; Disease Progression; Etidronic Acid; Filgrastim; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Male; Middle Aged; Organometallic Compounds; Prostate-Specific Antigen; Prostatic Neoplasms; Radionuclide Imaging; Radiotherapy; Recombinant Proteins; Rhenium | 2002 |